Drugs / Vurolenatide
Vurolenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04379856 | Jun → Dec 2020 | short bowel syndrome | 9 Meters Biopharma, Inc. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04988997 Comparator | Jun 2021 → Aug 2022 | short bowel syndrome | 9 Meters Biopharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vurolenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04988997 ↗ |
| Known as | GLP-1-XTEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095367 ↗ |
| Known as | NB-1001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095367 ↗ |
| Known as | NM-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04379856 ↗ |
| Known as | Vurolenatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095367 ↗ |
| Modality | Protein / enzyme biologic | “NM-002 is a fusion protein” NCT04379856 ↗ |
| Route | Subcutaneous | “Doses will be administered on Days 1 and 15 by subcutaneous injection” NCT04379856 ↗ |